Abstract Body

Background: HIV accessory proteins have been shown to antagonize a number of different host innate restriction mechanisms. In particular, HIV Vpu counteracts the inhibitory effect of Tetherin on particle release and also hampers Tetherin mediated activation of the NF-κB pathway. The role of HIV Vpu in regulating the interferon response to infection by degradation of the Interferon Regulatory Factor 3 (IRF3) has, however, been subject of conflicting reports. We therefore, systematically investigated the expression of IRF3 in primary human CD4+ T cells and macrophages infected with different HIV strains. In addition we also tested the ability of Vpu to interfere with innate immune signaling pathways like NF-κB and IRF3 pathway.

Methods: Primary CD4+ T cells and primary macrophages from several healthy donors were infected with different viruses and the levels of IRF3 were determined by both western blot analysis and intracellular staining. To assess the ability of HIV Vpu to interfere with innate immune pathways, we transfected Vpu into 293T together with different NF-kB or IRF3 reporter plasmids. We used TNF-alpha and transfection of IKKb to selectively activate NF-κB and overexpression of TBK1 to induce IRF3.

Results: Here we report that HIV Vpu variants from different viruses fail to degrade IRF3 in infected primary T lymphocytes and macrophages. We first analyzed by Western Blot the levels of IRF3 in uninfected cells or infected with a HIV wild-type virus or HIV lacking Vpu. We did not observe any changes in IRF3 expression levels. We also used an intracellular staining approach to directly compare the levels of IRF3 at a single cell level in the infected and uninfected cell population. We found that the percentage of IRF3 positive cells in the HIV infected population versus the uninfected was comparable.
In addition, we observed that HIV NL4.3 Vpu had no effect on IRF3 dependent gene expression in reporter assays while it is able to down-modulated NF-κB dependent transcription downstream IKKb activation. Moreover all tested HIV-1 Vpus retained the ability to down-modulated NF-κB activity.

Conclusions: Using different approaches we show that HIV Vpu does not affect the of IRF3 protein expression levels in primary cells during infection. Moreover, we found that Vpu is able to downregulate NFKB but IRF3 dependent transcription. Taken together, these results suggest that HIV Vpu regulates antiviral innate response by only acting on the NF-κB pathway.